What We Do
ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy.
ForSight VISION5’s lead product candidate is the HeliosTM insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The ocular insert rests under the eyelids and is formulated with a drug which releases onto the eye. This drug has previously been approved for intraocular pressure reduction in eye drop formulation. The Helios insert is currently in a multi-center, randomized, active controlled Phase 2 clinical study to assess the insert over the course of six months. ForSight VISION5 is also developing non-invasive, sustained release products for other major anterior segment eye diseases.